Celecoxib was noninferior to diclofenac plus omeprazole for preventing gastroduodenal ulcer recurrence in high-risk patients with arthritis: COMMENTARY

Denman, A. Michael
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p76
Academic Journal
This article reports that the study, which reported that celecoxib was noninferior to diclofenac plus omeprazole for preventing gastroduodenal ulcer recurrence in high-risk patients with arthritis, adds to the timely reappraisal of the earlier perception that cyclo-oxygenase (COX)-2 inhibitors reduce the incidence of gastroduodenal ulceration and bleeding compared with COX-1 inhibitors. This carefully designed and executed prospective blinded study compared the incidence of these complications in patients with arthritis receiving either the COX-2 inhibitor, celecoxib, or the COX-1 inhibitor, diclofenac, in combination with the proton-pump inhibitor and gastroprotective drug omeprazole.


Related Articles

  • Celecoxib Is as Effective as Diclofenac plus Omeprazole at Reducing Ulcer Bleeding. Chan, F. K;; Hung, L. C.; Suen, B. Y. // Annals of Internal Medicine;9/7/2004, Vol. 141 Issue 5, p375 

    This article presents information on effectiveness of various drugs used to treat ulcer bleeding. Current guidelines recommend that patients who are at risk for ulcer disease and require treatment for arthritis should receive either a cyclooxygenase-2 (COX-2) drug or a nonselective nonsteroidal...

  • Risk-Management for Persons at High Risk of GI Bleeding.  // Travel Medicine Advisor;Aug2007, Vol. 17 Issue 8, p16 

    The article discusses a study on the appropriate steps for risk reduction in patients taking NSAIDs. There is a risk of rebleeding in persons with a history of ulcer bleeding if traditional NSAID only is administered. The study revealed that COX-2 inhibitors should always be taken together with...

  • Peptic Ulcers.  // Current Medical Literature: Gastroenterology;2007, Vol. 26 Issue 3, p86 

    The article presents studies related to inflammatory bowel disease. These include "Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial," by F. K. Chan et al, "Proton...

  • Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. Scheiman, James M.; Yeomans, Neville D.; Talley, Nicholas J.; Vakil, Nimish; Chan, Francis K. L.; Tulassay, Zsolt; Rainoldi, Jorge L.; Szczepanski, Leszek; Ung, Kjell-Arne; Kleczkowski, Dariusz; Ahlbom, Henrik; Næsdal, Jørgen; Hawkey, Christopher // American Journal of Gastroenterology;Apr2006, Vol. 101 Issue 4, p701 

    OBJECTIVES: Proton pump inhibitors reduce ulcer recurrence in non-steroidal anti-inflammatory drug (NSAID) users, but their impact in at-risk ulcer-free patients using the current spectrum of prescribed agents has not been clearly defined. We assessed esomeprazole for ulcer prevention in at-risk...

  • Bleeding Peptic Ulcer in the Elderly. Zullo, Angelo; Hassan, Cesare; Campo, Salvatore M. A.; Morini, Sergio // Drugs & Aging;2007, Vol. 24 Issue 10, p815 

    Peptic ulcer bleeding is a frequent and dramatic event with both a high mortality rate and a substantial cost for healthcare systems worldwide. It has been found that age is an independent predisposing factor for gastrointestinal bleeding, with the risk increasing significantly in individuals...

  • Celecoxib most cost-effective choice in high-risk arthritis patients.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p12 

    Discusses research being done on the cost effectiveness of using celecoxib for treating high-risk patients with arthritis in the U.S. Reference to a study by M. Schaefer, M. DeLattre et al, published in the January 2005 issue of the "Current Medical Research and Opinion" journal; Comparison of...

  • LBOVI-A-4. Schneeweiss, S.; Solomon, D. H.; Wang, P. S.; Brookhart, A. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP83 

    Background: A direct comparison of the gastrointestinal (GI) and cardiac safety of NSAIDs in elderly patients is not possible based on randomized trials since different trials employed non-overlapping patient populations and comparison exposures. We sought to estimate the risk reduction of GI...

  • Small bowel injury induced by selective cyclooxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. Maehata, Yuji; Esaki, Motohiro; Morishita, Toshibumi; Kochi, Shuji; Endo, Shingo; Shikata, Kentaro; Kobayashi, Hiroyuki; Matsumoto, Takayuki // Journal of Gastroenterology;Apr2012, Vol. 47 Issue 4, p387 

    Background: Selective cyclooxygenase (COX)-2 inhibitors are less harmful to the small bowel mucosa than non-selective anti-inflammatory drugs. We aimed to compare the severity of small bowel mucosal injury in healthy volunteers induced by two selective COX-2 inhibitors, celecoxib and meloxicam,...

  • Independent Nurse: Journals Watch - Little evidence that COX-2s lower risk of serious GI side-effects.  // GP: General Practitioner;12/9/2005, p83 

    This article reports that a study of 9,407 patients in Great Britain, of whom 45 per cent had been prescribed a conventional NSAID in the previous three years and 10 per cent had been given a COX-2 inhibitor, found increased risks of serious gastrointestinal events associated with all the drugs...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics